GlaxoSmithKline (LON:GSK) Given New GBX 1,860 Price Target at Credit Suisse Group

GlaxoSmithKline (LON:GSK) had its price objective hoisted by Credit Suisse Group from GBX 1,800 ($23.68) to GBX 1,860 ($24.47) in a report issued on Thursday morning, Borsen Zeitung reports. They currently have a neutral rating on the stock.

A number of other analysts also recently issued reports on GSK. Goldman Sachs Group set a GBX 1,900 ($24.99) price objective on GlaxoSmithKline and gave the stock a buy rating in a research report on Wednesday, October 30th. UBS Group reissued a buy rating and set a GBX 1,900 ($24.99) price objective on shares of GlaxoSmithKline in a research report on Monday, December 2nd. Liberum Capital reissued a hold rating on shares of GlaxoSmithKline in a research report on Friday, November 15th. Societe Generale upped their price objective on GlaxoSmithKline from GBX 2,200 ($28.94) to GBX 2,300 ($30.26) and gave the stock a buy rating in a report on Thursday, January 9th. Finally, Barclays reissued an equal weight rating on shares of GlaxoSmithKline in a report on Friday, December 20th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of GBX 1,876.47 ($24.68).

Shares of LON GSK traded up GBX 38 ($0.50) during trading on Thursday, hitting GBX 1,846 ($24.28). 8,473,318 shares of the company were exchanged, compared to its average volume of 9,120,000. GlaxoSmithKline has a 12-month low of GBX 1,429.80 ($18.81) and a 12-month high of GBX 1,851.15 ($24.35). The company has a debt-to-equity ratio of 183.00, a quick ratio of 0.50 and a current ratio of 0.82. The company has a fifty day moving average price of GBX 1,776.73 and a 200-day moving average price of GBX 1,705.67. The firm has a market capitalization of $92.07 billion and a PE ratio of 20.22.

The business also recently disclosed a dividend, which was paid on Thursday, January 9th. Stockholders of record on Thursday, November 14th were given a GBX 19 ($0.25) dividend. The ex-dividend date was Thursday, November 14th. This represents a dividend yield of 1.07%. GlaxoSmithKline’s dividend payout ratio is currently 1.01%.

In related news, insider Vivienne Cox acquired 308 shares of GlaxoSmithKline stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of GBX 1,725 ($22.69) per share, for a total transaction of £5,313 ($6,988.95). Insiders bought 330 shares of company stock worth $569,837 over the last 90 days.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Recommended Story: What does the Producer Price Index (PPI) tell investors?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.